Long-term depot maintenance of chronic schizophrenic out-patients: the seven year follow-up of the Medical Research Council fluphenazine/placebo trial. II. The incidence of compliance problems, side-effects, neurotic symptoms and depression.
Seven years after the completion of the original trial, over 73% of patients were maintained on depot neuroleptics, and 70% had received such medication for over seven years. About 40% had presented with a problem of compliance at some time, and there was a significant correlation between poor compliance and in-patient admissions and schizophrenic relapses. The prevalence of parkinsonian side-effects, akathisia, and tardive dyskinesia was low. Non-psychotic symptoms were common, even in the absence of acute psychosis. Depression was found in a subgroup of patients; it was frequently reported as an indication for admission during follow-up period, and seemed to be part of the schizophrenic illness rather than a result of antipsychotic drug treatment.
D002986:Clinical Trials as Topic; D003692:Delayed-Action Preparations; D003866:Depressive Disorder / Q000150:complications*; D004311:Double-Blind Method; D004409:Dyskinesia, Drug-Induced / Q000209:etiology; D005476:Fluphenazine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005500:Follow-Up Studies; D006760:Hospitalization; D006801:Humans; D010302:Parkinson Disease, Secondary / Q000139:chemically induced; D010349:Patient Compliance; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology
D003692:Delayed-Action Preparations; C011825:fluphenazine depot; D005476:Fluphenazine